MARKETSPERPSLIVE83
Cash
Portfolio
TrendingElectionsPoliticsCultureSportsCryptoCommoditiesClimateEconomicsMentionsFinance

Tech & Science

PredictLive83AccountSocial

Medicine

Product
Kalshi ProPerpetual FuturesMarketsIncentive programInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQFee scheduleTrading hoursRegulatoryTrust Center
© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
All markets
AI
Big Tech & Business
Education
Energy
Market Share
Medicine
Physics & Math
Public Health
Space
Tokens
Medicine

When will Compass Pathways submit a NDA for COMP360 psilocybin?

before December
--
before November
--
$6 vol4 markets
Medicine

When will Beam Therapeutics submit a BLA for Risto-cel?

before November
13.4x
before December
--
$6 vol4 markets
Eli Lilly

Will the FDA approve VERVE-102?

Before 2030
--
Before 2031
--
$24 vol6 markets
Medicine

Will the FDA approve a cure for Type 1 diabetes before 2033?

Yes
--
No
1.01x
$19,005 vol1 market
Eli Lilly

Will the FDA approve retatrutide?

Before Jul 1, 2027
2.01x
Before Jan 1, 2027
1.01x
$15 vol5 markets
Medicine

Will the FDA approve camizestrant for advanced breast cancer?

Before Jan 1, 2027
1.01x
Before Jan 1, 2028
--
$58 vol2 markets
Medicine

When will the FDA approve Intellia Therapeutics’ lonvo-z?

Before July 2027
1.01x
Before 2028
--
$34 vol3 markets
Medicine

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

Before Jan 1, 2027
93.5x
Before 2028
--
$175 vol5 markets
Medicine

When will the FDA reclassify BPC-157 to Category 1?

Before November
--
Before 2027
--
$9 vol2 markets